Thomas Reiser: Final Day as Executive Director – Closing a Remarkable Chapter at ISTH
Thomas Reiser, Executive Director at the International Society on Thrombosis and Haemostasis, shared a post on LinkedIn:
“Today is my final day as Executive Director at the International Society on Thrombosis and Haemostasis (ISTH).
I close this remarkable 14+ year chapter with immense gratitude for the trust placed in me, for the privilege of serving a mission and organization I believe so deeply in, and for the many extraordinary people who made this journey meaningful every step of the way.
To the ISTH team, Council, volunteers, members, partners, and the hashtag#thrombosis and hashtag#hemostasis community around the world: Thank you for allowing me to be part of this amazing community, the collaboration, dedication, and the friendships that will stay with me long after today.
I leave with great pride for all we have been able to accomplish together.
At the same time, I look forward to continuing to create impact, wherever the next chapter may lead me.
With heartfelt thanks and deep appreciation.”

Find more posts featuring Thomas Reiser on Hemostasis Today.
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings
-
Apr 12, 2026, 21:15Katariina Öörni: Role of Cholesterol Absorption Efficiency in Atherosclerosis
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes